2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Sysnav: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg - Becker Muscular Dystrophy | Phase 2 | Completed | Edgewise Therapeutics, Inc. | 244 | 2022-11-10 | 2026-09-21 |
| Phase I/II Study of SRP-4053 in DMD Patients Placebo, SRP-4053 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Sarepta Therapeutics, Inc. | 39 | 2015-01-13 | 2020-10-19 |
Muscular Dystrophy, Duchenne (2)
France (2) · Italy (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Denmark (1) · Germany (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Spain (1)
Joanne Donovan, MD, PhD (1) · Roxana D. Dreghici (1)